India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain

Cadila Pharmaceuticals opens advanced pharmaceutical warehouse

FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use

Biocon Biologics launches Yesintek Biosimilar to Stelara in US

YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

Briefs: Syngene International and Cipla

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’

5.1 lakh TB patients notified across India

Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala

Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects